フォルテ・バイオサイエンシズ
Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -1.24 | $0 | -$19M |
| 2025 Q4 | -1.39 | $0 | -$16M |
| 2025 Q3 | -0.99 | $0 | -$14M |
| 2025 Q2 | -0.96 | $0 | -$10M |
| 2025 Q1 | -1.37 | $0 | -$10M |
| 2024 Q4 | -1.12 | $0 | -$10M |
| 2024 Q3 |
| -4.54 |
| $0 |
| -$8M |
| 2024 Q2 | -6.78 | $0 | -$6M |